1887

Abstract

Increasing levels of antibiotic resistance are complicating treatment for the sexually transmitted pathogen . Resistance to fluoroquinolones is associated with mutations in the gene. Although the precise mutations conferring resistance are not fully understood, the single nucleotide polymorphism (SNP) G248T/S83I is most implicated.

To evaluate the performance of the MG+(beta2) assay (SpeeDx, Australia), which detects single nucleotide polymorphisms (SNPs) in the gene at amino acid position S83 (A247C/S83R, G248T/S83I, G248A/S83N) and D87 (G259A/D87N, G259T/D87Y, G259C/D87H).

Clinical samples were analysed by MG+(beta2) assay and results compared to Sanger sequencing. Sensitivity, specificity, and predictive value for treatment failure were calculated.

From analysis of 205 samples, the MG+(beta2) assay performed with a high sensitivity 98.2% (95% CI:90.3–100) and specificity 99.3% (95% CI:96.3–100) for SNP detection with a kappa of 0.97 (95% CI:0.94–1.00). The predictive value of G248T/S83I detection (the most common SNP, prevalence of 13% in the study population) was analysed with respect to treatment failure (patients received sequential doxycycline-moxifloxacin). The positive-predictive-value for moxifloxacin failure after detection of S83I was only 44% (95% CI:24.4–65.1), while negative-predictive-value was high at 96.9% (95% CI:92.7–99.0), suggesting that other SNPs are contributing to resistance.

MG+(beta2) performed with high concordance compared to Sanger sequencing. Such qPCR assays can assist in understanding causes of treatment failure, inform the development of diagnostic assays, and can be applied to surveillance of mutations in populations. Due to an incomplete understanding of the basis for fluoroquinolone resistance, such tests do not appear to be ready for clinical application.

Funding
This study was supported by the:
  • SuzanneM. Garland , Department of Health and Human Services, State Government of Victoria , (Award VMRAF grant)
  • CatrionaS. Bradshaw , Department of Health and Human Services, State Government of Victoria , (Award VMRAF grant)
  • GeraldMurray , Department of Health and Human Services, State Government of Victoria , (Award VMRAF grant)
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001257
2021-02-19
2021-02-26
Loading full text...

Full text loading...

/deliver/fulltext/jmm/10.1099/jmm.0.001257/jmm001257.html?itemId=/content/journal/jmm/10.1099/jmm.0.001257&mimeType=html&fmt=ahah

References

  1. Horner PJ, Martin DH. Mycoplasma genitalium infection in men. J Infect Dis 2017; 216: S396 S405 [CrossRef] [PubMed]
    [Google Scholar]
  2. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis 2015; 61: 418 426 [CrossRef] [PubMed]
    [Google Scholar]
  3. Machalek DA, Tao Y, Shilling H, Jensen JS, Unemo M. Prevalence of macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infect Dis 2020; Accepted for publication 02 July 2020:
    [Google Scholar]
  4. Tabrizi SN, Su J, Bradshaw CS, Fairley CK, Walker S et al. Prospective evaluation of ResistancePlus Mg, a new multiplex quantitative PCR assay for detection of Mycoplasma genitalium and macrolide resistance. J Clin Microbiol 2017; 55: 1915 1919 [CrossRef] [PubMed]
    [Google Scholar]
  5. Read TRH, Murray GL, Danielewski JA, Fairley CK, Doyle M et al. Symptoms, sites, and significance of Mycoplasma genitalium in men who have sex with men. Emerg Infect Dis 2019; 25: 719 727 [CrossRef] [PubMed]
    [Google Scholar]
  6. Durukan D, Read TRH, Murray G, Doyle M, Chow EPF et al. Resistance-guided antimicrobial therapy using doxycycline-moxifloxacin and doxycycline-2.5g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability. Clin Infect Dis 2020; 71: 1017 1024 [CrossRef] [PubMed]
    [Google Scholar]
  7. Murray GL, Bradshaw CS, Bissessor M, Danielewski J, Garland SM et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium . Emerg Infect Dis 2017; 23: 809 812 [CrossRef] [PubMed]
    [Google Scholar]
  8. Couldwell DL, Tagg KA, Jeoffreys NJ, Gilbert GL. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int J STD AIDS 2013; 24: 822 828 [CrossRef] [PubMed]
    [Google Scholar]
  9. Murray GL, Bodiyabadu K, Danielewski J, Garland SM, Machalek DA. Moxifloxacin and sitafloxacin treatment failure in Mycoplasma genitalium infection: association with parC Mutation G248T (S83I) and concurrent gyrA mutations. J Infect Dis 2019; 221: 1017 1024
    [Google Scholar]
  10. Deguchi T, Maeda S, Tamaki M, Yoshida T, Ishiko H et al. Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. J Antimicrob Chemother 2001; 48: 742 744 [CrossRef] [PubMed]
    [Google Scholar]
  11. Tagg KA, Jeoffreys NJ, Couldwell DL, Donald JA, Gilbert GL. Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium . J Clin Microbiol 2013; 51: 2245 2249 [CrossRef] [PubMed]
    [Google Scholar]
  12. Shipitsyna E, Rumyantseva T, Golparian D, Khayrullina G, Lagos AC et al. Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia. PLoS One 2017; 12: e0175763 [CrossRef] [PubMed]
    [Google Scholar]
  13. Hadad R, Golparian D, Lagos AC, Ljungberg J, Nilsson P et al. Macrolide and fluoroquinolone resistance in Mycoplasma genitalium in two Swedish counties, 2011-2015. APMIS 2018; 126: 123 127 [CrossRef] [PubMed]
    [Google Scholar]
  14. Unemo M, Salado-Rasmussen K, Hansen M, Olsen AO, Falk M et al. Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016. Clin Microbiol Infect 2018; 24: 533 539 [CrossRef] [PubMed]
    [Google Scholar]
  15. Fernández-Huerta M, Bodiyabadu K, Esperalba J, Bradshaw CS, Serra-Pladevall J et al. Multicenter clinical evaluation of a novel multiplex real-time PCR (qPCR) assay for detection of fluoroquinolone resistance in Mycoplasma genitalium . J Clin Microbiol 2019; 57: e00886 00819 [CrossRef] [PubMed]
    [Google Scholar]
  16. BASHH UK Update to the 2015 BASHH UK national guideline on the management of non-gonococcal urethritis https://www.bashh.org/guidelines [accessed 30th June 2020]. 2018
  17. Australian STI Management Guidelines For Use in Primary Care http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium [accessed 30th June 2020]. 2018
  18. Horner PJ, Blee K, Falk L, van der Meijden W, Moi H. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS 2016; 27: 928 937 [CrossRef] [PubMed]
    [Google Scholar]
  19. CDC 2015 Sexually transmitted disease treatment guidelines. https://www.cdc.gov/std/tg2015/emerging.htm#myco [accessed 30th June 2020 2019].. 2015
  20. Manhart LE, Jensen JS. Quinolone resistance-associated mutations in Mycoplasma genitalium: not ready for prime time. Sex Transm Dis 2020; 47: 199 201 [CrossRef] [PubMed]
    [Google Scholar]
  21. Conway RJH, Cook S, Malone C, Bone S, Hassan-Ibrahim MO et al. Clearance of Mycoplasma genitalium infection with moxifloxacin in the presence of quinolone resistance-associated mutations. Sex Transm Dis 2020; 47: 197 198 [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001257
Loading
/content/journal/jmm/10.1099/jmm.0.001257
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error